Packaged Device Or Kit Patents (Class 435/810)
-
Patent number: 7074411Abstract: A recombinant heteromultimeric protein including at least (a) a polypeptide fusion molecule A consisting of a C4BP ?-chain C-terminal fragment and a polypeptide fragment heterologous to said ?-chain, and (a) a polypeptide fusion molecule B consisting of a C4BP ?-chain C-terminal fragment and a polypeptide fragment heterologous to said ?-chain, wherein (a) and (b) are linked in the C-terminal portion to form said multimeric protein.Type: GrantFiled: July 18, 1996Date of Patent: July 11, 2006Assignees: Universite Pierre et Marie Curie (Paris VI), Universite de Reims Champagne-ArdennesInventors: David Klatzmann, Jacques Cohen
-
Patent number: 7074610Abstract: An efficient method for the microfabrication of electronic devices which have been adapted for the analyses of biologically significant analyte species is described. The techniques of the present invention allow for close control over the dimensional features of the various components and layers established on a suitable substrate. Such control extends to those parts of the devices which incorporate the biological components which enable these devices to function as biological sensors. The materials and methods disclosed herein thus provide an effective means for the mass production of uniform wholly microfabricated biosensors. Various embodiments of the devices themselves are described herein which are especially suited for real time analyses of biological samples in a clinical setting. In particular, the present invention describes assays which can be performed using certain ligand/ligand receptor-based biosensor embodiments.Type: GrantFiled: August 30, 2001Date of Patent: July 11, 2006Assignee: i-Stat CorporationInventors: Stephen N. Cozzette, Graham Davis, Jeanne A. Itak, Imants R. Lauks, Randall M. Mier, Sylvia Piznik, Nicolaas Smit, Susan J. Steiner, Paul Van Der Werf, Henry J. Wieck
-
Patent number: 7070920Abstract: A screening device for performing an immunoassay test to detect the presence of a compound in a body fluid. The device includes a holder for removably receiving a membrane to which the fluid has been applied. A light is directed to the membrane. A photodetector measures the concentration of the light reflected back from the membrane. Specifically, the concentrations of reflected light from a control zone and a test zone are measured. Signals representative of the measured light concentrations are applied to a processor. If a specified concentration of predetermined light from a control zone on the membrane is detected, the processor considers the test to be successful. In the test is successful, the processor, based upon the measured concentration of reflected light from the test zone, generates data representative of the presence of the compound.Type: GrantFiled: January 12, 2001Date of Patent: July 4, 2006Assignee: Cozart Bioscience LimitedInventors: Robin James Spivey, Christopher William Hand, Dene Baldwin, Osborn Pierce Jones
-
Patent number: 7070945Abstract: A method for determining those patients suffering from mild cognitive impairment (MCI) who have a likelihood of progressing to Alzheimer's disease (AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.Type: GrantFiled: September 17, 2002Date of Patent: July 4, 2006Assignee: Syn X Pharma, Inc.Inventors: George Jackowski, Miyoko Takahashi
-
Patent number: 7067264Abstract: A test device (20) for detecting human blood includes a strip (22) having an introduction station (24), a test station (26), and a control station (28) disposed in spaced apart relationship. The test sample introduction station (24) has labeled antihuman Hb antibodies, the test station (26) has immobilized antihuman Hb antibodies, and the control station has immobilized polyclonal antibodies. A test sample (500) is deposited at the introduction station (24). If human hemoglobin is present in the test sample (500), a colored line will appear at the test station (26) and at the control station (28). If no human hemoglobin is present in the test sample (500), a colored line will only appear at the control station (28).Type: GrantFiled: July 23, 2001Date of Patent: June 27, 2006Inventor: Padma S. Bagaria
-
Patent number: 7060505Abstract: An assay device and method are provided which allow the determination of the presence or absence of at least one analyte in a test sample, while providing specific identification of the test subject. The assay device includes a reaction medium having at least one reaction zone and at least one control zone, which is capable of providing a pattern suitable for identifying the test subject. The pattern suitable for identifying the test subject is preferably a fingerprint. In a preferred embodiment of the invention, the reaction zone and the control zone include at least one member of a ligand/receptor pair.Type: GrantFiled: March 8, 2004Date of Patent: June 13, 2006Assignee: La Mina, Inc.Inventor: Raouf Guirguis
-
Patent number: 7052860Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.Type: GrantFiled: November 28, 2001Date of Patent: May 30, 2006Assignee: University of Florida Research FoundationInventors: Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
-
Patent number: 7052833Abstract: Disclosed is a region on human chromosome 1 that provides a genetic basis for absorptive hypercalciuria. The genes, proteins, and other biological materials provided are envisioned for use in diagnostic and therapeutic methods related to absorptive hypercalciuria and osteoporosis with hypercalciuria.Type: GrantFiled: June 23, 1999Date of Patent: May 30, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Berenice Y. Reed-Gitomer, Charles Y. C. Pak
-
Patent number: 7049129Abstract: The invention provides an apparatus and method for detection of a target molecule. The apparatus includes a probe labeled with a transition metal-ligand complex that hybridizes with the target to form an initial complex, a metal ion for doping the initial complex and forming a final complex, and a potential means for providing a potential to the final complex to produce a detectable signal indicating the presence of the target after redox reaction. The method of the invention teaches the steps of hybridizing a probe with an attached label to the target to produce an initial complex, adding a metal ion to the initial complex to form a final complex and applying a potential to the final complex to produce a measurable signal.Type: GrantFiled: April 15, 2003Date of Patent: May 23, 2006Assignee: Agilent Technologies, Inc.Inventors: Ganapati R. Mauze, Dan-Hui Yang
-
Patent number: 7049130Abstract: An improved multi-layered diagnostic sanitary test strip for receiving a heterogenous fluid, such as whole blood, to test for presence and/or amount of a suspected analyte in the fluid by facilitating a color change in the strip corresponding to the amount of the analyte in the fluid, wherein the test strip includes fluid volume control dams to prevent spillage of the fluid from the strip and a chemical reagent solution that facilitates end-point testing.Type: GrantFiled: March 21, 2005Date of Patent: May 23, 2006Assignee: Home Diagnostics, Inc.Inventors: Patrick Carroll, Jon Schneider, Douglas E. Bell
-
Patent number: 7045602Abstract: An antibody which recognizes an active hepatocyte growth factor activator (HGFA) and does not substantially recognize inactive HGFA is provided. Also disclosed is a monoclonal antibody thereof, and a hybridoma cell line for producing the monoclonal antibody. There is further provided a method for measuring active HGFA using the antibody, and a method for detecting a disease, by detecting or measuring active HGFA using the antibody.Type: GrantFiled: December 4, 2001Date of Patent: May 16, 2006Assignee: Mitsubishi Chemical CorporationInventors: Daiji Naka, Kazuhiko Nagaike
-
Patent number: 7045342Abstract: The invention provides an improved test cell for detecting the presence of an analyte in a liquid sample. The device has an elongate casing defining a liquid sample inlet, a reservoir volume, a test volume, and a window through the casing at the test volume. Disposed within the cell is a sample absorbent, a novel biphasic substrate and a reservoir, together capable of transporting an aqueous solution within the casing along a flow path extending from the sample inlet through the test volume and into the reservoir volume. The invention further comprises a method for detecting the presence of an analyte in a liquid sample using the device and a biphasic chromatographic material for carrying out the method.Type: GrantFiled: March 5, 2004Date of Patent: May 16, 2006Assignee: Church & Dwight Co., Inc.Inventors: Albert Nazareth, Mary Beth Boyle, Yea-Shun Cheng
-
Patent number: 7041458Abstract: The present invention relates to an assay for free protein S comprising the addition of a ligand specific for free protein S to a biological fluid sample to form a protein S/ligand complex, and subsequent determination of the amount of the complex formed in the sample. The ligand specific for free protein S is comprised of the C4b binding protein (C4BP), or part thereof, or a compound comprising an amino acid residue sequence that binds specifically to the binding site for C4BP in protein S. The present invention further relates to antibodies specific for free protein S, which can be used as ligands in the assay of the invention, and with protein S related polypeptides, which can be used to produce such antibodies. In addition, the present invention is related to diagnostic test systems, suitable in kit form, comprising the present ligand and at least one further reagent required in the assay for free protein S.Type: GrantFiled: December 21, 2001Date of Patent: May 9, 2006Assignee: T.A.C. Thrombosis and Coagulation AktiebolagInventor: Björn Dahlbäck
-
Patent number: 7041509Abstract: The present invention provides novel microfluidic devices and methods that are useful for performing high-throughput screening assays. In particular, the devices and methods of the invention are useful in screening large numbers of different compounds for their effects on a variety of chemical, and preferably, biochemical systems.Type: GrantFiled: April 2, 2002Date of Patent: May 9, 2006Assignee: Caliper Life Sciences, Inc.Inventors: J. Wallace Parce, Anne R. Kopf-Sill, Luc J. Bousse
-
Patent number: 7038018Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention further relates to a method of modulating a function of Bonzo, and to the use of the antibodies, antigen-binding fragments, targeting molecules and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: August 27, 2001Date of Patent: May 2, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
-
Patent number: 7037670Abstract: Several synthetic peptides modeled after Ser31 in tyrosine hydroxylase (“Ser31 peptides”) have been developed and evaluated as in vitro substrates for assaying the activity of extracellular signal-regulated protein kinase 1 and 2 (“ERK1/2”). The phosphorylation of the Ser31 peptides by activated, recombinant ERK2 was found to exhibit catalytic efficiencies (Vmax/Km) up to 4-fold higher than that of a synthetic myelin basic protein (MBP)-based peptide. Several synthetic peptides were tested using cellular extracts from PC12 rat pheochromocytoma cells, both untreated cells and cells treated with nerve growth factor. Although the phosphorylation of the MBP peptide by extracts of PC12 cells was higher than that of the Ser31 peptide, the relative treatment-dependent increase was much greater for the Ser31 peptide and the pattern of ERK1/2 activation more closely mimicked the pattern seen with more complicated assays that initially isolated ERK1/2 from other kinases in the cellular extracts.Type: GrantFiled: April 19, 2002Date of Patent: May 2, 2006Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: John W. Haycock
-
Patent number: 7030228Abstract: The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.Type: GrantFiled: November 15, 2000Date of Patent: April 18, 2006Assignee: Miltenyi Biotec GmbHInventors: Juergen Schmitz, Andrzej Dzionek, David William Buck
-
Patent number: 7018830Abstract: Disclosed are devices for detecting the presence of a preselected analyte in a fluid sample. The devices comprise a substrate microfabricated to define a sample inlet port, and a mesoscale flow system that includes a sample flow channel extending from the inlet port. The mesoscale flow system further includes an analyte detection region in fluid communication with the flow channel comprised of a binding moiety for specifically binding the analyte. The detection region is constructed with a mesoscale dimension sufficiently small to enhance binding of the binding moiety and the analyte. The binding moiety may be immobilized in the detection region. The mesoscale detection systems of the invention may be used in a wide range of applications, including the detection of cells or macromolecules, or for monitoring reactions or cell culture growth.Type: GrantFiled: January 21, 2003Date of Patent: March 28, 2006Assignee: The Trustees of the University of PennsylvaniaInventors: Peter Wilding, Larry J. Kricka, Jay N. Zemel
-
Patent number: 7018849Abstract: Superparamagnetic (“SPM”) subunits of 1–30 nm average mean diameter (e.g. ferro fluid) subparticles are treated with a magnetically noninterfering substance capable of coating and covering them (e.g, BSA) and they spontaneously form agglomerates of about 100 nm to about 450 nm or higher average mean diameter and are then used to form complexes with target biological ligands such as viruses, contained in large volumes of liquid. The complexes are subjected to the gradient intensity of a strong magnetic field, and excess liquid is removed, where upon an immunochromatographic assay is conducted to determine the identity and/or amount of target ligand present, in which operation SPM particles that bonded to the ligand function as tags for ligand detection.Type: GrantFiled: January 15, 2002Date of Patent: March 28, 2006Inventors: Roger N. Piasio, Nathan Turner
-
Patent number: 7018847Abstract: An assay device for determining an analyte in an aqueous sample comprises: (i) an elongate flow matrix (6) allowing lateral transport of fluid therethrough by capillary action, wherein the matrix comprises a liquid application zone (3) and downstream thereof, a detection zone (8) having an immobilized capture agent capable of directly or indirectly binding to said analyte, (ii) a wicking member (13) placed at the downstream end of the flow matrix and having an upstream end and a downstream end, and (iii) a time indicator (14) placed downstream of the detection zone (8) for indicating when liquid applied to the liquid application zone has reached the time indicator. The time indicator comprises an indicator substance or substance combination which is capable of exhibiting a visible color change when hydrated by the aqueous sample.Type: GrantFiled: May 4, 2001Date of Patent: March 28, 2006Assignee: Pharmacia Diagnostics ABInventors: Ib Mendel-Hartvig, Erik Unger
-
Patent number: 7005276Abstract: The present invention relates to novel nucleic acid molecules encoding a Rhesus D antigen contributing to the weak D phenotype which are characterized by one or a combination of missense mutations or by a gene conversion involving exons 6 to 9 of the RHD and RHCE genes. The present invention further relates to vectors comprising the nucleic acid molecules of the invention, to hosts transformed with said vectors, to proteins encoded by said nucleic acid molecules and to methods of producing such polypeptides. The fact that missense mutations and the conversion referred to above can be directly correlated to the weak D phenotype has a significant impact on the routine testing of blood samples. For example, oligonucleotides and antibodies can now be designed that generally allow the detection of weak D phenotypes in a sample. Such oligonucleotides, antibodies as well as a variety of diagnostic methods all fall within the scope of the present invention.Type: GrantFiled: December 18, 1998Date of Patent: February 28, 2006Assignee: DRK Blutspendedienst Baden-Württember GGmbHInventors: Willy A. Flegel, Franz F. Wagner
-
Patent number: 7005292Abstract: Disclosed are devices for detecting the presence of a preselected analyte in a fluid sample. The devices comprise a substrate microfabricated to define a sample inlet port, and a mesoscale flow system that includes a sample flow channel extending from the inlet port. The mesoscale flow system further includes an analyte detection region in fluid communication with the flow channel comprised of a binding moiety for specifically binding the analyte. The detection region is constructed with a mesoscale dimension sufficiently small to enhance binding of the binding moiety and the analyte. The binding moiety may be immobilized in the detection region. The mesoscale detection systems of the invention may be used in a wide range of applications, including the detection of cells or macromolecules, or for monitoring reactions or cell culture growth.Type: GrantFiled: August 22, 2003Date of Patent: February 28, 2006Assignee: The Trustees of the University of PennsylvaniaInventors: Peter Wilding, Larry J. Kricka, Jay N. Zemel
-
Patent number: 7001775Abstract: A method and kit for screening a sample of body fluid for at least one autoantibody to at least one antigen. A source of at least one antigen to the autoantibody is provided. A substrate having immobilized thereto at least one antibody to the antigen is also provided. The antigen source is contacted with the sample of body fluid, so as to obtain a mixture wherein the antigen is allowed to substantially bind with the autoantibody, when the latter is present in the sample of body fluid. The mixture is allowed to flow relative to the substrate so as to allow the mixture to contact the antibody immobilized to the substrate. Labeling means are provided to permit monitoring of binding of the autoanitbody and the antigen present in the mixture, so as to provide an indication of the presence of the autoanitbody in the sample of body fluid.Type: GrantFiled: October 27, 1999Date of Patent: February 21, 2006Assignee: RSR LimitedInventors: Peter John Burne, Bernard Rees Smith
-
Patent number: 6998108Abstract: A novel ligand (p30) for herpes virus entry mediator, HVEM, is provided. p30 is useful for modulating immune responses and in inhibiting infection by herpes virus. Methods for treating subjects with lymphoid cell disorders or those having or suspected of having a herpes virus infection, utilizing p30 of the invention, are also provided.Type: GrantFiled: March 13, 2000Date of Patent: February 14, 2006Assignee: La Jolla Institute for Allergy and ImmunologyInventor: Carl E. Ware
-
Patent number: 6998273Abstract: A device for collecting oral liquids includes a lateral flow chromatography strip having a collection pad for insertion into the mouth. The collection pad is separated from the remainder of the chromatography strip by a liquid impermeable removable barrier which prevents liquid in the collection pad from entering the chromatography strip. Once adequate oral liquid has been collected (as indicated by a sample sufficiency indicator), the device is withdrawn from the mouth and the barrier is removed to allow oral liquids to flow through the strip. The liquids interact with binding partners in the strip to provide test results, such as an indication that an analyte of interest is present in the liquid. The strip may be contained in a housing with an access opening through which the removable barrier may be manipulated, and windows through which test results may be viewed. This device avoids reflux of reagents from the strip into the mouth of a test subject during use.Type: GrantFiled: April 1, 2002Date of Patent: February 14, 2006Assignee: A-Fem Medical CorporationInventors: William H. Fleming, Timothy P. Hyatt, Dudley B. Thomas
-
Patent number: 6995240Abstract: The immunoglobulin heavy chain binding protein BiP(GRP78), or a fragment thereof, provides a reagent for indicating the presence of rheumatoid arthritis (RA). The protein used is a recombinant BiP(GRP78) having a defined sequence. A prognostic and/or diagnostic test for RA may be an ELISA or a Western Blot that utilizes the BiP(GRP78) protein or a fragment thereof. Also disclosed are a method of testing for RA using BiP(GRP78) or a cDNA sequence coding therefor. Further disclosed is a method of treating RA by the BiP(GRP78) protein or corresponding cDNA.Type: GrantFiled: October 8, 1999Date of Patent: February 7, 2006Assignee: King's College LondonInventors: Gabriel Stavros Panayi, Valerie Mary Corrigall, Mark Duncan Bodman-Smith, Mark Stewart Fife, Jeremy Shaun Lanchbury
-
Patent number: 6991940Abstract: An improved multi-layered diagnostic sanitary test strip for receiving a heterogenous fluid, such as whole blood, to test for presence and/or amount of a suspected analyte in the fluid by facilitating a color change in the strip corresponding to the amount of the analyte in the fluid, wherein the test strip includes fluid volume control dams to prevent spillage of the fluid from the strip and a chemical reagent solution that facilitates end-point testing.Type: GrantFiled: October 31, 2001Date of Patent: January 31, 2006Assignee: Home Diagnostics, Inc.Inventors: Patrick Carroll, Jon Schneider, Douglas E. Bell
-
Patent number: 6991912Abstract: Novel magnetic assay methods and systems. According to a preferred embodiment, a chromatographic medium, which preferably comprises a test strip, is provided that is designed to be contacted with a test solution having activated magnetic particles such that the solution flows bilaterally thereacross. A magnetic field, generated by a magnet or electromagnet, is selectively applied to the medium which causes the charged particles to become substantially bound at a site on the medium specified by the position of the magnet, to thus form a captured line or zone. In one preferred embodiment, the magnetic field is applied at the site on the medium at which the test solution is contacted. The degree of magnetic force applied to the membrane may be selectively adjusted to vary the width or surface area of the capture line or zone.Type: GrantFiled: February 5, 2002Date of Patent: January 31, 2006Assignee: Wavesesense, LLCInventor: Christopher Feistel
-
Patent number: 6989144Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein V1, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the exposure vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 30, 2000Date of Patent: January 24, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Samatha J. Busfield, Jean-Luc Villeval, Martine Jandrot-Perrus, William Vainchencker, Davinder Singh Gill, Ming Diana Qian, Gillian Kingsbury
-
Patent number: 6977173Abstract: Disclosed is a testing device and methods for the identification of an analyte of interest in a sample. In a preferred embodiment, the testing device includes a front panel having at least one sample application aperture; a rear panel having at least one solvent application aperture; a sample collection matrix disposed between the rear panel and the front panel, the sample collection matrix being in communication with the sample and solvent application apertures of the front and rear panels; and at least one insertable test strip containing a reagent enabling detection of the analyte of interest.Type: GrantFiled: January 18, 2001Date of Patent: December 20, 2005Assignee: Enterix, Inc.Inventor: Howard Milne Chandler
-
Patent number: 6974699Abstract: A method of releasing an agent for example, a chemotherapeutic, under predetermined conditions by protecting the agent within a lipid structure such as a liposome, causing lipase activity to be constituted by combining two or more components, e.g., recombinant N- or C-terminal Clostridium perfringens alpha-toxin fragments, one of these components being conjugated to a targeting molecule e.g., an antibody which binds to a target such as a tumor antigen. The lipid structure is then exposed to the constituted lipase activity such as to release the agent. Also disclosed are materials and kits for use in the method.Type: GrantFiled: November 21, 2001Date of Patent: December 13, 2005Assignee: Biovation LimitedInventors: Richard W Titball, Francis J Carr
-
Patent number: 6969488Abstract: An apparatus and system are provided for simultaneously analyzing a plurality of analytes anchored to microparticles. Microparticles each having a uniform population of a single kind of analyte attached are disposed as a substantially immobilized planar array inside of a flow chamber where steps of an analytical process are carried out by delivering a sequence of processing reagents to the microparticles by a fluidic system under microprocessor control. In response to such process steps, an optical signal is generated at the surface of each microparticle which is characteristic of the interaction between the analyte carried by the microparticle and the delivered processing reagent. The plurality of analytes are simultaneously analyzed by collecting and recording images of the optical signals generated by all the microparticles in the planar array.Type: GrantFiled: July 17, 2001Date of Patent: November 29, 2005Assignee: Solexa, Inc.Inventors: John Bridgham, Kevin Corcoran, George Golda, Sydney Brenner, Michael C. Pallas
-
Patent number: 6967081Abstract: This invention concerns a method for the assessment of bone fragility and fracture risk, or osteoporosis, in a person. In said method, the concentration of gamma-carboxylated osteocalcin (COC) and optionally also the concentration of intact or total osteocalcin (IOC or TOC, respectively) in a body fluid sample of said person is measured. The concentration of gamma-carboxylated osteocalcin (COC) so obtained is compared to the mean concentration of gamma-carboxylated osteocalcin (mean COC) in similar body fluid samples of the population of the same age and sex. Alternatively, the determined ratio COC/IOC or COC/TOC for said person, is compared to the mean ratio COC/IOC or COC/TOC, (mean ratio COC/IOC or mean ratio COC/TOC) determined from measurements in similar body fluid samples of the population of the same age and sex. A measured COC that is lower than the mean COC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person.Type: GrantFiled: March 20, 2000Date of Patent: November 22, 2005Inventors: Sanna-Maria Käkönen, Heikki Luukinen, Kim Pettersson, Timo Lövgren, H. Kalervo Väänänen
-
Patent number: 6965018Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: GrantFiled: June 6, 2001Date of Patent: November 15, 2005Assignee: Bristol-Myers Squibb CompanyInventors: Glen E Mikesell, Han Chang, Robert J. Peach
-
Patent number: 6960467Abstract: The invention relates to a microfluidic device with microchannels that have separated regions which have a member of a specific binding pair member such as DNA or RNA bound to porous polymer, beads or structures fabricated into the microchannel. The microchannels of the invention are fabricated from plastic and are operatively associated with a fluid propelling component and detector.Type: GrantFiled: December 19, 2001Date of Patent: November 1, 2005Assignee: Clinical Micro Sensors, Inc.Inventors: Chan-Long Shieh, Barbara Foley, Huinan Yu, Vi-En Choong
-
Patent number: 6955874Abstract: Kits for the multiplexed detection of known, selected nucleotide target sequences are provided. Detection involves the release of identifying tags as a consequence of target recognition. The kits include sets of electrophoretic tag probes or e-tag probes, capture agent and optionally a nuclease. The e-tag probes comprise a detection region and a mobility-defining region called the mobility modifier, both linked to a target-binding moiety. In using the kits, the target-binding moiety of the e-tag probes hybridizes to complementary target sequences followed by nuclease cleavage of the e-tag probes and release of detectable e-tags or e-tag reporters. The mixture is exposed to a capture agent which binds uncleaved and/or partially cleaved e-tag probes, followed by electrophoretic separation. In a multiplexed assay, different released e-tag reporters may be separated and detected providing for target identification.Type: GrantFiled: April 2, 2001Date of Patent: October 18, 2005Assignee: Aclara Biosciences, Inc.Inventors: Sharat Singh, Tracy Matray, Ahmed Chenna
-
Patent number: 6951761Abstract: This disclosure relates to CryoArrays, which permit the analysis of samples (such as protein, nucleic acid, virus, or cell samples) in arrays that are prepared at low temperatures. Because CryoArrays are constructed as a block of substantially columnar samples, the block can be sliced to provide a plurality of identical or substantially identical individual arrays. The individual arrays can be used for parallel analysis of the same array feature set, for instance with different probes or under different conditions. Also provided are methods of making CryoArrays, devices for making CryoArrays, and kits.Type: GrantFiled: August 30, 2002Date of Patent: October 4, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Robert A. Star, Takehiko Miyaji, Stephen M. Hewitt, Lance A. Liotta
-
Patent number: 6949626Abstract: Disclosed are Bacillus thuringiensis strains comprising novel crystal proteins which exhibit insecticidal activity against coleopteran insects including red flour beetle larvae (Tribolium castaneum) and Japanese beetle larvae (Popillia japonica). Also disclosed are novel B. thuringiensis crystal toxin genes, designated cryET33 and cryET34, which encode the colepteran-toxic crystal proteins, CryET33 (29-kDa) crystal protein, and the cryET34 gene encodes the 14-kDa CryET34 crystal protein. The CryET33 and CryET34 crystal proteins are toxic to red flour beetle larvae and Japanese beetle larvae. Also disclosed are methods of making and using transgenic cells comprising the novel nucleic acid sequences of the invention.Type: GrantFiled: September 10, 2001Date of Patent: September 27, 2005Assignee: Monsanto Technology LLCInventors: William P. Donovan, Judith C. Donovan, Annette C. Slaney
-
Patent number: 6946255Abstract: The invention provides monoclonal antibodies, which specifically react with a Fas ligand, or active fragments thereof, a production process of the monoclonal antibodies, which specifically react with a Fas ligand, hybridomas separately producing a monoclonal antibody, which specifically reacts with a Fas ligand present on a cell surface, a method of detecting a Fas ligand in a solution, and a kit for use in detecting a Fas ligand, comprising plurality of monoclonal antibodies against Fas ligand in combination.Type: GrantFiled: March 21, 1996Date of Patent: September 20, 2005Assignee: Ko OkumuraInventors: Nobuhiko Kayagaki, Hideo Yagita, Ko Okumura, Motomi Nakata
-
Patent number: 6939677Abstract: A polypeptide has the antibody binding activity of the 46 Kdalton HMFG differentiation antigen and/or homology to at least one of the light chains of clotting factors V and VIII and is also provided as a fusion protein with a second antigenic polypeptide. An antibody has affinity for the polypeptide of the invention or a functional fragment thereof in vivo and in vitro methods for therapy vaccination and detecting the presence of the polypeptide, the antibody, the DNA and RNA of the invention are provided. DNA and RNA sequences encode the polypeptide of the invention or fragments thereof and immunoassay kits comprise the antibodies and/or polypeptides of the invention.Type: GrantFiled: June 7, 1995Date of Patent: September 6, 2005Assignee: Cancer Research Fund of Contra CostaInventors: Roberto Luis Ceriani, Jerry Arthur Peterson, David James Larocca
-
Patent number: 6930168Abstract: The invention provides peptide compositions and methods of making and using therapeutic compositions comprising peptides for the treatment of a subject having a demyelinating condition.Type: GrantFiled: January 24, 2002Date of Patent: August 16, 2005Assignee: The President and Fellows of Harvard CollegeInventors: Jack L. Strominger, Masha Fridkis-Hareli
-
Patent number: 6929920Abstract: Methods of determining Chronic Obstructive Pulmonary Disease (COPD) severity in patients which comprises measuring the concentration of soluble E-cadherin (sE-cadherin) in the patient's urine and/or blood serum and determining the extent of severity by reference to correlation graphs, a method of treating patients with COPD, methods for determining the responsiveness of said patients to said treatment and a prognostic product for detecting the concentration of sE-cadherin in urine and/or blood serum.Type: GrantFiled: May 25, 2000Date of Patent: August 16, 2005Assignee: Glaxo Group LimitedInventor: Michael Robert West
-
Patent number: 6927211Abstract: Compositions and methods are provided for use in the treatment of cancer.Type: GrantFiled: December 4, 2003Date of Patent: August 9, 2005Assignee: Bristol-Myers Squibb CompanyInventors: Giorgio Minotti, Luca Gianni
-
Patent number: 6927204Abstract: Compositions, methods, and devices are provided for inducing or enhancing the growth, proliferation, regeneration of inner ear tissue, particularly inner ear hair cells. In addition, provided are compositions and methods for prophylactic or therapeutic treatment of a mammal afflicted with an inner ear disorder or condition, particularly for hearing impairments involving hair cell damage, loss, or degeneration, by administration of a therapeutically effective amount of IGF-1 or FGF-2, or their agonists, alone or in combination.Type: GrantFiled: June 9, 2003Date of Patent: August 9, 2005Assignee: Genentech, Inc.Inventor: Wei-Qiang Gao
-
Patent number: 6924095Abstract: The present invention features an isolated, intact virus associated with human lymphoma, and originally isolated from a mantle cell lymphoma, referred to herein as a mantle histiocyte retrovirus (MHRV). The invention also features compositions and methods for detecting MHRV, as well as methods and compositions for propagating MHRV in vitro, screening for anti-MHRV agents, and generation of attenuated MHRV strains.Type: GrantFiled: August 15, 2002Date of Patent: August 2, 2005Assignee: The Regents of the University of CaliforniaInventors: Micahael S. McGrath, Brian Herndier
-
Patent number: 6924153Abstract: This invention provides solid phase specific binding lateral flow assay methods, devices and kits for quantitating high and low molecular weight analytes. The methods and devices of the invention employ labelled reagents which are either analyte analogs or complementary specific binding pair members for the analyte and a novel arrangement of capture zones comprising immobilized specific binding substances for either the analyte or the labelled reagent to effect bound from unbound labelled reagent as a function of analyte concentration. The capture zones are disposed on a non-bibulous matrix defining a flow path from a sample receiving zone to the capture zone. The devices of this invention also include multilane flow paths and multiple capture zones to quantitate analyte.Type: GrantFiled: March 6, 1997Date of Patent: August 2, 2005Assignee: Quidel CorporationInventors: Hans Boehringer, Gerald Rowley, Allan Pronovost
-
Patent number: 6919434Abstract: A protein which inhibits osteoclast diffraction and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions an SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.Type: GrantFiled: June 23, 1999Date of Patent: July 19, 2005Assignee: Sankyo Co., Ltd.Inventors: Masaaki Goto, Eisuke Tsuda, Shin'ichi Mochizuki, Kazuki Yano, Fumie Kobayashi, Nobuyuki Shima, Hisataka Yasuda, Nobuaki Nakagawa, Tomonori Morinaga, Masatsugu Ueda, Kanji Higashio
-
Patent number: 6911320Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTTG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.Type: GrantFiled: September 7, 2001Date of Patent: June 28, 2005Assignee: Cedars-Sinai Medical CenterInventors: Shlomo Melmed, Lin Pei
-
Patent number: 6908897Abstract: Provided herein is a heretofore unknown insulin analogue, a pharmaceutical composition comprising such an insulin analogue, as well as processes for preparing such an insulin analogue and such a pharmaceutical composition.Type: GrantFiled: August 23, 2001Date of Patent: June 21, 2005Assignee: Aventis Pharma Deutschland GmbHInventors: Dietrich Brandenburg, Chantalle Havenith
-
Patent number: 6905714Abstract: The present invention relates generally to a method for modulating steroidogenic activity and a composition useful for same. The present invention further relates to a composition comprising a steroidogenic modulator useful for modulating physiological processes mediated by the androgen receptor or an active form thereof or complex comprising same and/or for modulating physiological processes mediated by estrogen receptors. The composition of the present invention preferably comprises an extract of herbs or botanical or horticultural equivalents of the herbs or chemical or functional equivalents of one or more components of the herbal extract thereof.Type: GrantFiled: February 27, 2001Date of Patent: June 14, 2005Assignee: National University of SingaporeInventors: Yek Cheng Ong, Eu Leong Yong